Loading...
XSTO
MNTC
Market cap38mUSD
Jul 09, Last price  
13.30SEK
1D
1.53%
1Q
0.00%
IPO
-79.57%
Name

Mentice AB

Chart & Performance

D1W1MN
XSTO:MNTC chart
P/E
P/S
1.34
EPS
Div Yield, %
Shrs. gr., 5y
2.97%
Rev. gr., 5y
15.21%
Revenues
279m
-3.87%
108,966,000157,048,000149,370,000137,503,000185,064,000217,954,000273,610,000290,329,000279,093,000
Net income
-32m
L+75.54%
6,182,00020,148,000-20,600,000-13,092,000-29,191,000-30,665,000-2,817,000-18,420,000-32,334,000
CFO
-20m
L
15,731,00016,005,000-37,282,00030,534,000-5,130,00014,908,00036,517,00017,919,000-20,299,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Mentice AB (publ), founded in 1998 and headquartered in Gothenburg, Sweden, specializes in delivering advanced endovascular simulation solutions. These are utilized by educational institutions, healthcare systems, and medical device manufacturers globally, with the company's operations spanning across Europe, the Middle East, Africa, the Asia Pacific region, and the Americas. Its business is structured across distinct segments focusing on the Medical Device Industry, Healthcare Systems, and Strategic Alliances. The company offers a comprehensive suite of software modules designed for training in a wide array of interventional procedures. These include acute ischemic stroke, atrial septal defect/patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee, carotid, and renal interventions, along with patient-specific simulations. The portfolio further encompasses advanced and essential coronary procedures, intermediate coronary, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic and uterine artery embolization, radiation safety, transarterial chemoembolization, transseptal puncture, vascular trauma, and cardiac rhythm management. Additionally, Mentice provides crucial support for interventionalists transitioning from transfemoral to transradial access techniques. Beyond software, Mentice's product line features sophisticated medical simulators for endovascular therapies, accompanied by compatible accessories and extensions. They also supply specialized silicone vasculature, as well as cardiac, vascular, and neurovascular flow systems. Innovative digital offerings include the Mentice Right Heart Cath App, a mobile tool for interactive exploration of right heart catheterization procedures, and the Mentice Live Learning Center, which facilitates remote learning through its VIST G endovascular simulation platform. All these comprehensive solutions are engineered to educate, train, and significantly enhance the skills of medical professionals.
IPO date
Jun 18, 2019
Employees
114
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT